TNF and autoimmune disease: In preclinical models of autoimmune diseases including CIA, lupus, and psoriasis, these TLR antagonists have been shown to inhibit Th1, Th17, and inflammasome pathways and suppress production of cytokines such as TNF, IL-12, IL-6, and IL-17 (80, 81).